COMMUNIQUÉS West-GlobeNewswire

AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
27/09/2024
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ET OCALA, Fla., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or [...]
33 Medical Wins 2024 Best Technology in Spine Award for Innovative NuvoDisc® Device
27/09/2024
Boca Raton, FL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- 33 Medical, Inc., a leader in cutting-edge spinal health innovations, is proud to announce that its NuvoDisc ® medical device has been awarded the prestigious 2024 Best [...]
WeightWatchers Announces Executive Leadership Transition
27/09/2024
Independent Board Member Tara Comonte Will Serve as Interim Chief Executive Officer Sima Sistani Will Step Down as CEO and Director NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“ [...]
ImPact Biotech Announces 50% Enrollment in Phase 3 ENLIGHTED Clinical Trial of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer
27/09/2024
Phase 3 ENLIGHTED study enrollment completion expected by first quarter of 2025 TEL AVIV, Israel, Sept. 27, 2024 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing [...]
Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed
27/09/2024
GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital
27/09/2024
– Retiring $17.5 million in Avenue Capital debt and entering into a $11.5 million loan agreement with an insider-led investor group – – Eliminating $12 million in scheduled debt payments through June 2026 – – $11.5 [...]
Venus Concept Announces $15 million Debt-to-Equity Exchange Transaction
27/09/2024
Second Substantial Reduction of Existing Debt by Madryn Asset Management in 2024; the Company has reduced its debt balance by 54% year-to-date TORONTO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus [...]
Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
27/09/2024
– Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 – – Retiring $17.5 million in Avenue Capital debt, aided by $11.5 million in new debt from insider-led group; [...]
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
27/09/2024
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and [...]
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
27/09/2024
WATERTOWN, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the [...]
Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines
27/09/2024
New patent expected to provide market exclusivity into 2036 Zembrace ® SymTouch ® (sumatriptan succinate injection) 10mg is indicated for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 27, 2024 (GLOBE [...]
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
27/09/2024
Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark phase 3 [...]
Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO
27/09/2024
Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO Cette approbation fait suite à celle obtenue dans l’Union européenne pour le traitement des adultes atteints de bronchopneumopathie [...]
Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes
27/09/2024
Modic Changes (MC) are MRI Findings Associated With Endplate Damage, Neoinnervation, and Chronic Low Back Pain (cLBP) MR Spectroscopy (MRS) Measurement of Intradiscal Propionic Acid (PA) can Clarify MC Etiology and Help [...]
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
27/09/2024
Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which everyone can live a healthy and productive life, free from the preventable suffering, stigma, [...]
Nexstim Receives Order for NBS System 5 in Finland
27/09/2024
Press release, Helsinki, 27 September 2024 at 10 AM (EEST) Nexstim Receives Order for NBS System 5 in Finland Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received order from a Finnish hospital for an NBS System [...]
Information on the total number of voting rights and shares
27/09/2024
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), September 27, 2024 , 08:05 am CET / 2:05 am ET – In accordance with article 15 of the Law of 2 May 2007 on [...]
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
26/09/2024
-Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April [...]
Cue Biopharma Announces Proposed Public Offering
26/09/2024
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]

Pages